Maria RosÃ¡rio Almeida

List of Publications by Year
in descending order

52 papers	1,879 citations	218677 26 h-index	265206 42 g-index
54 all docs	54 docs citations	54 times ranked	1821 citing authors

#	Article	IF	Citations
1	Choroid Plexus in Alzheimerâ€™s Diseaseâ€”The Current State of Knowledge. Biomedicines, 2022, 10, 224.	3.2	23
2	In Vitro and In Vivo Effects of SerpinA1 on the Modulation of Transthyretin Proteolysis. International Journal of Molecular Sciences, 2021, 22, 9488.	4.1	7
3	SERPINA1 modulates expression of amyloidogenic transthyretin. Experimental Cell Research, 2020, 395, 112217.	2.6	7
4	Modulation of the Mechanisms Driving Transthyretin Amyloidosis. Frontiers in Molecular Neuroscience, 2020, 13, 592644.	2.9	24
5	Targeting transthyretin amyloidosis in the eye with next-generation stabilizers: AT40 displays potent TTR stabilization in the human vitreous. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 73-74.	3.0	2
6	Lead optimization of resilient next-generation transthyretin stabilizers for multiple target-product profiles: approaching the CNS. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 77-78.	3.0	1
7	Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis. International Journal of Molecular Sciences, 2019, 20, 1287.	4.1	28
8	Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation. Scientific Reports, 2017, 7, 44709.	3.3	16
9	Curcumin: A multi-target disease-modifying agent for late-stage transthyretin amyloidosis. Scientific Reports, 2016, 6, 26623.	3.3	38
10	Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nature Communications, 2016, 7, 10787.	12.8	139
11	Impairment of autophagy by TTR V30M aggregates: inÂvivo reversal by TUDCA and curcumin. Clinical Science, 2016, 130, 1665-1675.	4.3	11
12	A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition. European Journal of Medicinal Chemistry, 2016, 121, 823-840.	5.5	17
13	Tuning Transthyretin Amyloidosis Inhibition Properties of Iododiflunisal by Combinatorial Engineering of the Nonsalicylic Ring Substitutions. ACS Combinatorial Science, 2015, 17, 32-38.	3.8	16
14	Transthyretin chemical chaperoning by flavonoids: Structureâ€“activity insights towards the design of potent amyloidosis inhibitors. Biochemistry and Biophysics Reports, 2015, 3, 123-133.	1.3	20
15	Gene therapy approach to FAP: in vivo influence of T119M in TTR deposition in a transgenic V30M mouse model. Gene Therapy, 2014, 21, 1041-1050.	4.5	10
16	Molecular Tweezers Targeting Transthyretin Amyloidosis. Neurotherapeutics, 2014, 11, 450-461.	4.4	41
17	Dietary curcumin counteracts extracellular transthyretin deposition: Insights on the mechanism of amyloid inhibition. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 39-45.	3.8	43
18	Transthyretin Deposition in Familial Amyloidotic Polyneuropathy. Current Medicinal Chemistry, 2012, 19, 2304-2311.	2.4	52

#	Article	IF	Citations
19	Clearance of extracellular misfolded proteins in systemic amyloidosis: Experience with transthyretin. FEBS Letters, 2012, 586, 2891-2896.	2.8	25
20	Natural polyphenols as modulators of TTR amyloidogenesis: in vitro and in vivo evidences towards therapy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 39-42.	3.0	26
21	Epigallocatechin-3-Gallate as a Potential Therapeutic Drug for TTR-Related Amyloidosis: â€œIn Vivoâ€• Evidence from FAP Mice Models. PLoS ONE, 2012, 7, e29933.	2.5	94
22	Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Letters, 2011, 585, 2424-2430.	2.8	133
23	Functional characterization of Arabidopsis thaliana transthyretin-like protein. BMC Plant Biology, 2010, 10, 30.	3.6	39
24	Human metallothioneins 2 and 3 differentially affect amyloidâ€beta binding by transthyretin. FEBS Journal, 2010, 277, 3427-3436.	4.7	25
25	Iodine Atoms: A New Molecular Feature for the Design of Potent Transthyretin Fibrillogenesis Inhibitors. PLoS ONE, 2009, 4, e4124.	2.5	51
26	Binding of epigallocatechinâ€3â€gallate to transthyretin modulates its amyloidogenicity. FEBS Letters, 2009, 583, 3569-3576.	2.8	122
27	Isatin derivatives, a novel class of transthyretin fibrillogenesis inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5270-5273.	2.2	44
28	Substrate specificity of transthyretin: identification of natural substrates in the nervous system. Biochemical Journal, 2009, 419, 467-474.	3.7	45
29	Iodination of salicylic acid improves its binding to transthyretin. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 512-517.	2.3	16
30	Transthyretin Interacts with Metallothionein 2. Biochemistry, 2008, 47, 2244-2251.	2.5	34
31	Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 517-522.	3.8	57
32	Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design. Biochemical Journal, 2007, 408, 131-138.	3.7	30
33	Interaction with human plasminogen system turns on proteolytic activity in Streptococcus agalactiae and enhances its virulence in a mouse model. Microbes and Infection, 2007, 9, 1276-1284.	1.9	39
34	In Vitro and in Vivo Effects of Genistein on Ttr Stabilization and Aggregation. , 2007, , 113-115.		0
35	The binding of xanthone derivatives to transthyretin. Biochemical Pharmacology, 2005, 70, 1861-1869.	4.4	30
36	Small Transthyretin (TTR) Ligands as Possible Therapeutic Agents in TTR Amyloidoses. CNS and Neurological Disorders, 2005, 4, 587-596.	4.3	54

#	Article	IF	Citations
37	Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochemical Journal, 2004, 381, 351-356.	3.7	88
38	Comparative Studies of Two Transthyretin Variants with Protective Effects on Familial Amyloidotic Polyneuropathy: TTR R104H and TTR T119M. Biochemical and Biophysical Research Communications, 2000, 270, 1024-1028.	2.1	61
39	Unusual Self-Association Properties of Transthyretin Y114C Related to Familial Amyloidotic Polyneuropathy: Effects on Detection and Quantification. Biochemical and Biophysical Research Communications, 1999, 261, 264-269.	2.1	14
40	Thyroxine binding to transthyretin Met 119. Endocrine, 1997, 6, 309-315.	2.3	90
41	Screening and biochemical characterization of transthyretin variants in the Portuguese population. Human Mutation, 1997, 9, 226-233.	2.5	41
42	Thyroxine binding to transthyretin (TTR) variantsâ€"two variants (TTR Pro 55 and TTR Met 111) with a particularly low binding affinity. European Journal of Endocrinology, 1996, 135, 226-230.	3.7	17
43	Haplotype analysis of common transthyretin mutations. Human Genetics, 1995, 96, 350-4.	3.8	21
44	TTR exon scanning in peripheral neuropathies. Neuromuscular Disorders, 1995, 5, 187-191.	0.6	18
45	TTR Leu 64 in an FAP kindred identified by PCR-RFLP analysis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1994, 1, 184-185.	3.0	1
46	Transthyretin ALA 71: A new transthyretin variant in a Spanish family with familial amyloidotic polyneuropathy. Human Mutation, 1993, 2, 420-421.	2.5	16
47	Two transthyretin variants (TTR Ala-49 and TTR Gln-89) in two sicilian kindreds with hereditary amyloidosis. Human Mutation, 1992, 1, 211-215.	2.5	44
48	Amyloidogenic and nonâ€amyloidogenic transthyretin Asn 90 variants. Clinical Genetics, 1992, 42, 27-30.	2.0	8
49	Characterization of a basic transthyretin variant - TTR Arg 102 - in the German population. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1991, 1097, 224-226.	3.8	16
50	Transthyretin Leu 68 in a form of cardiac amyloidosis. Basic Research in Cardiology, 1991, 86, 567-571.	5.9	39
51	Prenatal diagnosis of familial amyloidotic polyneuropathy: evidence for an early expression of the associated transthyretin methionine 30. Human Genetics, 1990, 85, 623-6.	3.8	33
52	Familial amyloidotic polyneuropathy: transthyretin (prealbumin) variants in kindreds of Italian origin. Human Genetics, 1988, 80, 341-343.	3.8	12